Generic drug prices are falling and usage is on the rise. But are plan sponsors taking full opportunity of the potential savings by maximizing the use of generic drugs?
Coverage of the 2012 Value of Generic Drugs Symposium delves into this question, while also examining Canada’s drug review system and provincial drug pricing policies.
New controversial couponing practices are discussed, and a case study offers valuable lesson in how to introduce a generic substitution policy.
More than half (59 per cent) of global institutional investors have yet to discuss artificial intelligence with their managers, according to a new survey from...
Treating obesity with all available evidence-based tools ultimately costs less than not treating it, according to panellists during a webinar hosted by Benefits Canada and...
Finance Minister Chrystia Freeland says today’s fall economic statement will remove the cap that currently restricts Canadian pension funds from owning more than 30 per...
The keynote session at Benefits Canada’s 2024 Defined Contribution Investment Forum warned that the failure to plan for the ‘boomer bulge’ is affecting private and...
In an increasingly polarized world, discussing politics in the workplace can be harmful to employees and negatively impact company culture, says Jasmine Escalera, a career...
The mental health of Canadian workers has dropped below levels last seen at the start of the coronavirus pandemic, driven by a steep decline in...
The OPSEU Pension Trust has reduced its financed emissions intensity by 11 per cent when compared to 2022, according to the investment organization’s latest climate...
From the unlocking of pension benefits in Nova Scotia to new pay transparency rules in Ontario, stories about pension and employment legislation caught the eyes...
